Document is current
Any future updates will be listed below
-
Authors
Wallmann, Georg https://orcid.org/0000-0003-4749-3730
Skowronek, Patricia https://orcid.org/0000-0002-8441-6067
Brennsteiner, Vincenth
Lebedev, Mikhail https://orcid.org/0009-0008-3646-7899
Thielert, Marvin
Steigerwald, Sophia
Kotb, Mohamed
Despard, Oscar
Heymann, Tim https://orcid.org/0000-0002-6984-6894
Zhou, Xie-Xuan
Strauss, Maximilian T. https://orcid.org/0000-0003-3320-6833
Ammar, Constantin
Willems, Sander https://orcid.org/0000-0002-7124-610X
Schwörer, Magnus
Zeng, Wen-Feng https://orcid.org/0000-0003-4325-2147
Mann, Matthias https://orcid.org/0000-0003-1292-4799
-
Funding
Funding for this research was provided by:
Max-Planck-Gesellschaft
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
EC | Horizon 2020 Framework Programme (874839)
Bavarian State Ministry of Health and Care through the research project DigiMed Bayern (www.digimed-bayern.de).
- License Information
-
More Information
Article History
Received: 25 June 2024
Accepted: 24 July 2025
First Online: 21 October 2025
Competing interests
: M.M. is an indirect investor in Evosep. G.W. is founder of Aplusia, a biotech consultancy. The other authors declare no competing interests.
